Workflow
CodeEvolver technology platform
icon
Search documents
Codexis to Report Third Quarter 2025 Financial Results on November 6
Globenewswire· 2025-10-23 11:05
Core Viewpoint - Codexis, Inc. will report its financial results for Q3 2025 on November 6, 2025, and will host a conference call to discuss these results and provide a business update [1]. Company Overview - Codexis is a leading provider of enzymatic solutions aimed at efficient and scalable manufacturing of complex therapeutics, utilizing its proprietary CodeEvolver technology platform [3]. - The company is developing the ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route [3]. - Codexis' enzymes are designed to address challenges in small molecule pharmaceuticals manufacturing and nucleic acid synthesis, offering benefits such as higher yields, reduced energy usage, and improved efficiency [3].
Codexis to Report Second Quarter 2025 Financial Results on August 13
Globenewswire· 2025-07-30 20:05
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop and enhance novel, high- performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeuti ...
Codexis to Report First Quarter 2025 Financial Results on May 14
Globenewswire· 2025-04-30 20:05
Core Viewpoint - Codexis, Inc. will report its financial results for Q1 2025 on May 14, 2025, and will host a conference call to discuss these results and provide a business update [1]. Company Overview - Codexis is a leading provider of enzymatic solutions aimed at efficient and scalable therapeutics manufacturing, utilizing its proprietary CodeEvolver technology platform to enhance high-performance enzymes [3]. - The company is developing the ECO Synthesis™ manufacturing platform to facilitate the scaled production of RNAi therapeutics through an enzymatic process [3]. - Codexis enzymes are designed to address challenges in small molecule pharmaceuticals manufacturing and nucleic acid synthesis, offering benefits such as higher yields, reduced energy consumption, and improved efficiency in manufacturing [3].